Development of a First-in-Class RIPK1 Degrader to Enhance Antitumor Immunity
Cited by 1
Related Papers
Pharmacological targeting of MYC-regulated IRE1/XBP1 pathway suppresses MYC-driven breast cancer
|Journal of Clinical Investigation|2018|260
Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry
|Nature Communications|2020|204
Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors
|Science|2023|103